

Press release
27 April, 2022

Resolutions of the Annual General Meeting of Curasight A/S

Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held its Annual General Meeting on 27 April 2022 at 10:00 (CET) at the Company’s premises, Ole Maaløes Vej 3, room M7, DK-2200 Copenhagen N, Denmark.

Today, Curasight A/S (“Curasight” or the “Company”) adopted the following resolutions at its Annual General Meeting:

Presentation and approval of the annual report

The General Meeting adopted the annual report for the financial year 2021.

Appropriation of profit or covering of loss as recorded in the adopted annual report

The General Meeting adopted the Board of Directors’ proposal to carry forward the result for 2021 to the next year in accordance with the adopted annual report for 2021.

Election of members to the Board of Directors

The General Meeting re-elected the following members of the Board of Directors:

- Per Falholt
- Lars Trolle
- Andreas Kjær
- Charlotte Vedel
- Kirsten Aarup Drejer
- Ulrich Krasilnikoff

Election of auditor

The General Meeting re-elected PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as auditor of the Company.

Amendment of the Articles of Association

The General Meeting adopted a proposal to amend the Articles of Association in accordance with the updated version of the Articles of Association attached to the notice convening the Annual General Meeting.

Authorisations to increase the share capital

The General Meeting adopted a resolution to authorise the Board of Directors to increase the share capital with and without pre-emption rights until 26 April 2027.

Incentive Programs (Authorisations to issue warrants)

The General Meeting adopted authorisations to the Board of Directors to issue warrants for the purpose of establishing incentive programs for the Board of Directors, the Executive Management and employees of the Company.

Authorisation to the chairman of the meeting

The General Meeting adopted a resolution to authorise the chairman of the meeting to apply for registration of the resolutions passed and to make certain amendments, if necessary.

At the board meeting held immediately after the Annual General Meeting, Per Falholt was re-elected chairman and Lars Trolle vice-chairman of the Board of Directors.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.